Global Alpha 1 Antitrypsin Deficiency Treatment Market Insights and Forecast to 2028

Report ID: 1228104 | Published Date: Jan 2025 | No. of Page: 110 | Base Year: 2024 | Rating: 4 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Business Overview
    1.1 Study Scope
    1.2 Market Analysis by Indication
        1.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Indication, 2017 VS 2021 VS 2028
        1.2.2 Augmentation Therapy
        1.2.3 Cystic Fibrosis(CF)
        1.2.4 Non-CF Bronchiectasis(NCFB)
        1.2.5 Diabetes
        1.2.6 Other
    1.3 Market by End Users
        1.3.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by End Users, 2017 VS 2021 VS 2028
        1.3.2 COPD
        1.3.3 Cystic Fibrosis(CF)
        1.3.4 Non-CF Bronchiectasis(NCFB)
        1.3.5 Diabetes
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Perspective (2017-2028)
    2.2 Alpha 1 Antitrypsin Deficiency Treatment Growth Trends by Region
        2.2.1 Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by Region (2017-2022)
        2.2.3 Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Region (2023-2028)
    2.3 Alpha 1 Antitrypsin Deficiency Treatment Market Dynamics
        2.3.1 Alpha 1 Antitrypsin Deficiency Treatment Industry Trends
        2.3.2 Alpha 1 Antitrypsin Deficiency Treatment Market Drivers
        2.3.3 Alpha 1 Antitrypsin Deficiency Treatment Market Challenges
        2.3.4 Alpha 1 Antitrypsin Deficiency Treatment Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Alpha 1 Antitrypsin Deficiency Treatment Players by Revenue
        3.1.1 Global Top Alpha 1 Antitrypsin Deficiency Treatment Players by Revenue (2017-2022)
        3.1.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Players (2017-2022)
    3.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Alpha 1 Antitrypsin Deficiency Treatment Revenue
    3.4 Global Alpha 1 Antitrypsin Deficiency Treatment Market Concentration Ratio
        3.4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Alpha 1 Antitrypsin Deficiency Treatment Revenue in 2021
    3.5 Alpha 1 Antitrypsin Deficiency Treatment Key Players Head office and Area Served
    3.6 Key Players Alpha 1 Antitrypsin Deficiency Treatment Product Solution and Service
    3.7 Date of Enter into Alpha 1 Antitrypsin Deficiency Treatment Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Alpha 1 Antitrypsin Deficiency Treatment Breakdown Data by Indication
    4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by Indication (2017-2022)
    4.2 Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Indication (2023-2028)
5 Alpha 1 Antitrypsin Deficiency Treatment Breakdown Data by End Users
    5.1 Global Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by End Users (2017-2022)
    5.2 Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by End Users (2023-2028)
6 North America
    6.1 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size (2017-2028)
    6.2 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication
        6.2.1 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017-2022)
        6.2.2 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2023-2028)
        6.2.3 North America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Indication (2017-2028)
    6.3 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users
        6.3.1 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017-2022)
        6.3.2 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2023-2028)
        6.3.3 North America Alpha 1 Antitrypsin Deficiency Treatment Market Share by End Users (2017-2028)
    6.4 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country
        6.4.1 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022)
        6.4.2 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028)
        6.4.3 United States
        6.4.4 Canada
7 Europe
    7.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size (2017-2028)
    7.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication
        7.2.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017-2022)
        7.2.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2023-2028)
        7.2.3 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Share by Indication (2017-2028)
    7.3 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users
        7.3.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017-2022)
        7.3.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2023-2028)
        7.3.3 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Share by End Users (2017-2028)
    7.4 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country
        7.4.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022)
        7.4.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size (2017-2028)
    8.2 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication
        8.2.1 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017-2022)
        8.2.2 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2023-2028)
        8.2.3 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Share by Indication (2017-2028)
    8.3 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users
        8.3.1 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017-2022)
        8.3.2 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2023-2028)
        8.3.3 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Share by End Users (2017-2028)
    8.4 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region
        8.4.1 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2017-2022)
        8.4.2 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2023-2028)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia 
9 Latin America
    9.1 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size (2017-2028)
    9.2 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication
        9.2.1 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017-2022)
        9.2.2 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2023-2028)
        9.2.3 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Indication (2017-2028)
    9.3 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users
        9.3.1 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017-2022)
        9.3.2 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2023-2028)
        9.3.3 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Share by End Users (2017-2028)
    9.4 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country
        9.4.1 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022)
        9.4.2 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028)
        9.4.3 Mexico
        9.4.4 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size (2017-2028)
    10.2 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication
        10.2.1 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017-2022)
        10.2.2 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2023-2028)
        10.2.3 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Share by Indication (2017-2028)
    10.3 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users
        10.3.1 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017-2022)
        10.3.2 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2023-2028)
        10.3.3 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Share by End Users (2017-2028)
    10.4 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country
        10.4.1 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022)
        10.4.2 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE
11 Key Players Profiles
    11.1 Pfizer
        11.1.1 Pfizer Company Details
        11.1.2 Pfizer Business Overview
        11.1.3 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Introduction
        11.1.4 Pfizer Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
        11.1.5 Pfizer Recent Developments
    11.2 GlaxoSmithKline
        11.2.1 GlaxoSmithKline Company Details
        11.2.2 GlaxoSmithKline Business Overview
        11.2.3 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Introduction
        11.2.4 GlaxoSmithKline Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
        11.2.5 GlaxoSmithKline Recent Developments
    11.3 AstraZeneca
        11.3.1 AstraZeneca Company Details
        11.3.2 AstraZeneca Business Overview
        11.3.3 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Introduction
        11.3.4 AstraZeneca Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
        11.3.5 AstraZeneca Recent Developments
    11.4 Boehringer Ingelheim
        11.4.1 Boehringer Ingelheim Company Details
        11.4.2 Boehringer Ingelheim Business Overview
        11.4.3 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Introduction
        11.4.4 Boehringer Ingelheim Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
        11.4.5 Boehringer Ingelheim Recent Developments
    11.5 Teva Pharmaceutical Industries
        11.5.1 Teva Pharmaceutical Industries Company Details
        11.5.2 Teva Pharmaceutical Industries Business Overview
        11.5.3 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Introduction
        11.5.4 Teva Pharmaceutical Industries Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
        11.5.5 Teva Pharmaceutical Industries Recent Developments
    11.6 Takeda
        11.6.1 Takeda Company Details
        11.6.2 Takeda Business Overview
        11.6.3 Takeda Alpha 1 Antitrypsin Deficiency Treatment Introduction
        11.6.4 Takeda Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
        11.6.5 Takeda Recent Developments
    11.7 Baxter
        11.7.1 Baxter Company Details
        11.7.2 Baxter Business Overview
        11.7.3 Baxter Alpha 1 Antitrypsin Deficiency Treatment Introduction
        11.7.4 Baxter Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
        11.7.5 Baxter Recent Developments
    11.8 Grifols
        11.8.1 Grifols Company Details
        11.8.2 Grifols Business Overview
        11.8.3 Grifols Alpha 1 Antitrypsin Deficiency Treatment Introduction
        11.8.4 Grifols Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
        11.8.5 Grifols Recent Developments
    11.9 CSL Behring
        11.9.1 CSL Behring Company Details
        11.9.2 CSL Behring Business Overview
        11.9.3 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Introduction
        11.9.4 CSL Behring Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
        11.9.5 CSL Behring Recent Developments
    11.10 Kamada Ltd
        11.10.1 Kamada Ltd Company Details
        11.10.2 Kamada Ltd Business Overview
        11.10.3 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Introduction
        11.10.4 Kamada Ltd Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
        11.10.5 Kamada Ltd Recent Developments
    11.11 Chiesi Pharmaceuticals
        11.11.1 Chiesi Pharmaceuticals Company Details
        11.11.2 Chiesi Pharmaceuticals Business Overview
        11.11.3 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Introduction
        11.11.4 Chiesi Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
        11.11.5 Chiesi Pharmaceuticals Recent Developments
    11.12 Kedrion Group
        11.12.1 Kedrion Group Company Details
        11.12.2 Kedrion Group Business Overview
        11.12.3 Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Introduction
        11.12.4 Kedrion Group Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
        11.12.5 Kedrion Group Recent Developments
    11.13 Vertex Pharmaceuticals
        11.13.1 Vertex Pharmaceuticals Company Details
        11.13.2 Vertex Pharmaceuticals Business Overview
        11.13.3 Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Introduction
        11.13.4 Vertex Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
        11.13.5 Vertex Pharmaceuticals Recent Developments
    11.14 ProMetic Life Sciences
        11.14.1 ProMetic Life Sciences Company Details
        11.14.2 ProMetic Life Sciences Business Overview
        11.14.3 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Introduction
        11.14.4 ProMetic Life Sciences Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
        11.14.5 ProMetic Life Sciences Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Author Details
    13.3 Disclaimer
List of Tables
    Table 1. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Indication (US$ Million), 2017 VS 2021 VS 2028
    Table 2. Key Players of Augmentation Therapy
    Table 3. Key Players of Cystic Fibrosis(CF)
    Table 4. Key Players of Non-CF Bronchiectasis(NCFB)
    Table 5. Key Players of Diabetes
    Table 6. Key Players of Other
    Table 7. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by End Users (US$ Million), 2017 VS 2021 VS 2028
    Table 8. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 9. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2017-2022) & (US$ Million)
    Table 10. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region (2017-2022)
    Table 11. Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 12. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region (2023-2028)
    Table 13. Alpha 1 Antitrypsin Deficiency Treatment Market Trends
    Table 14. Alpha 1 Antitrypsin Deficiency Treatment Market Drivers
    Table 15. Alpha 1 Antitrypsin Deficiency Treatment Market Challenges
    Table 16. Alpha 1 Antitrypsin Deficiency Treatment Market Restraints
    Table 17. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Players (2017-2022) & (US$ Million)
    Table 18. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Players (2017-2022)
    Table 19. Global Top Alpha 1 Antitrypsin Deficiency Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Alpha 1 Antitrypsin Deficiency Treatment as of 2021)
    Table 20. Ranking of Global Top Alpha 1 Antitrypsin Deficiency Treatment Companies by Revenue (US$ Million) in 2021
    Table 21. Global 5 Largest Players Market Share by Alpha 1 Antitrypsin Deficiency Treatment Revenue (CR5 and HHI) & (2017-2022)
    Table 22. Key Players Headquarters and Area Served
    Table 23. Key Players Alpha 1 Antitrypsin Deficiency Treatment Product Solution and Service
    Table 24. Date of Enter into Alpha 1 Antitrypsin Deficiency Treatment Market
    Table 25. Mergers & Acquisitions, Expansion Plans
    Table 26. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017-2022) & (US$ Million)
    Table 27. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Indication (2017-2022)
    Table 28. Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Indication (2023-2028) & (US$ Million)
    Table 29. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Indication (2023-2028)
    Table 30. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017-2022) & (US$ Million)
    Table 31. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by End Users (2017-2022)
    Table 32. Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by End Users (2023-2028) & (US$ Million)
    Table 33. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by End Users (2023-2028)
    Table 34. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017-2022) & (US$ Million)
    Table 35. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2023-2028) & (US$ Million)
    Table 36. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017-2022) & (US$ Million)
    Table 37. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2023-2028) & (US$ Million)
    Table 38. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022) & (US$ Million)
    Table 39. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028) & (US$ Million)
    Table 40. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017-2022) & (US$ Million)
    Table 41. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2023-2028) & (US$ Million)
    Table 42. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017-2022) & (US$ Million)
    Table 43. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2023-2028) & (US$ Million)
    Table 44. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022) & (US$ Million)
    Table 45. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028) & (US$ Million)
    Table 46. Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017-2022) & (US$ Million)
    Table 47. Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2023-2028) & (US$ Million)
    Table 48. Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017-2022) & (US$ Million)
    Table 49. Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2023-2028) & (US$ Million)
    Table 50. Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2017-2022) & (US$ Million)
    Table 51. Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2023-2028) & (US$ Million)
    Table 52. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017-2022) & (US$ Million)
    Table 53. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2023-2028) & (US$ Million)
    Table 54. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017-2022) & (US$ Million)
    Table 55. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2023-2028) & (US$ Million)
    Table 56. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022) & (US$ Million)
    Table 57. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028) & (US$ Million)
    Table 58. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017-2022) & (US$ Million)
    Table 59. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2023-2028) & (US$ Million)
    Table 60. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017-2022) & (US$ Million)
    Table 61. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2023-2028) & (US$ Million)
    Table 62. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022) & (US$ Million)
    Table 63. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028) & (US$ Million)
    Table 64. Pfizer Company Details
    Table 65. Pfizer Business Overview
    Table 66. Pfizer Alpha 1 Antitrypsin Deficiency Treatment Product
    Table 67. Pfizer Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
    Table 68. Pfizer Recent Developments
    Table 69. GlaxoSmithKline Company Details
    Table 70. GlaxoSmithKline Business Overview
    Table 71. GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Product
    Table 72. GlaxoSmithKline Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
    Table 73. GlaxoSmithKline Recent Developments
    Table 74. AstraZeneca Company Details
    Table 75. AstraZeneca Business Overview
    Table 76. AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Product
    Table 77. AstraZeneca Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
    Table 78. AstraZeneca Recent Developments
    Table 79. Boehringer Ingelheim Company Details
    Table 80. Boehringer Ingelheim Business Overview
    Table 81. Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Product
    Table 82. Boehringer Ingelheim Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
    Table 83. Boehringer Ingelheim Recent Developments
    Table 84. Teva Pharmaceutical Industries Company Details
    Table 85. Teva Pharmaceutical Industries Business Overview
    Table 86. Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Product
    Table 87. Teva Pharmaceutical Industries Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
    Table 88. Teva Pharmaceutical Industries Recent Developments
    Table 89. Takeda Company Details
    Table 90. Takeda Business Overview
    Table 91. Takeda Alpha 1 Antitrypsin Deficiency Treatment Product
    Table 92. Takeda Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
    Table 93. Takeda Recent Developments
    Table 94. Baxter Company Details
    Table 95. Baxter Business Overview
    Table 96. Baxter Alpha 1 Antitrypsin Deficiency Treatment Product
    Table 97. Baxter Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
    Table 98. Baxter Recent Developments
    Table 99. Grifols Company Details
    Table 100. Grifols Business Overview
    Table 101. Grifols Alpha 1 Antitrypsin Deficiency Treatment Product
    Table 102. Grifols Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
    Table 103. Grifols Recent Developments
    Table 104. CSL Behring Company Details
    Table 105. CSL Behring Business Overview
    Table 106. CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Product
    Table 107. CSL Behring Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
    Table 108. CSL Behring Recent Developments
    Table 109. Kamada Ltd Company Details
    Table 110. Kamada Ltd Business Overview
    Table 111. Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Product
    Table 112. Kamada Ltd Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
    Table 113. Kamada Ltd Recent Developments
    Table 114. Chiesi Pharmaceuticals Company Details
    Table 115. Chiesi Pharmaceuticals Business Overview
    Table 116. Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product
    Table 117. Chiesi Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
    Table 118. Chiesi Pharmaceuticals Recent Developments
    Table 119. Kedrion Group Company Details
    Table 120. Kedrion Group Business Overview
    Table 121. Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Product
    Table 122. Kedrion Group Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
    Table 123. Kedrion Group Recent Developments
    Table 124. Vertex Pharmaceuticals Company Details
    Table 125. Vertex Pharmaceuticals Business Overview
    Table 126. Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product
    Table 127. Vertex Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
    Table 128. Vertex Pharmaceuticals Recent Developments
    Table 129. ProMetic Life Sciences Company Details
    Table 130. ProMetic Life Sciences Business Overview
    Table 131. ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Product
    Table 132. ProMetic Life Sciences Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
    Table 133. ProMetic Life Sciences Recent Developments
    Table 134. Research Programs/Design for This Report
    Table 135. Key Data Information from Secondary Sources
    Table 136. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Indication: 2021 VS 2028
    Figure 2. Augmentation Therapy Features
    Figure 3. Cystic Fibrosis(CF) Features
    Figure 4. Non-CF Bronchiectasis(NCFB) Features
    Figure 5. Diabetes Features
    Figure 6. Other Features
    Figure 7. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by End Users: 2021 VS 2028
    Figure 8. COPD Case Studies
    Figure 9. Cystic Fibrosis(CF) Case Studies
    Figure 10. Non-CF Bronchiectasis(NCFB) Case Studies
    Figure 11. Diabetes Case Studies
    Figure 12. Alpha 1 Antitrypsin Deficiency Treatment Report Years Considered
    Figure 13. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 14. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 15. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region: 2021 VS 2028
    Figure 16. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Players in 2021
    Figure 17. Global Top Alpha 1 Antitrypsin Deficiency Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Alpha 1 Antitrypsin Deficiency Treatment as of 2021)
    Figure 18. The Top 10 and 5 Players Market Share by Alpha 1 Antitrypsin Deficiency Treatment Revenue in 2021
    Figure 19. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY (2017-2028) & (US$ Million)
    Figure 20. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size Market Share by Indication (2017-2028)
    Figure 21. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size Market Share by End Users (2017-2028)
    Figure 22. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size Share by Country (2017-2028)
    Figure 23. United States Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 24. Canada Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 25. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY (2017-2028) & (US$ Million)
    Figure 26. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size Market Share by Indication (2017-2028)
    Figure 27. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size Market Share by End Users (2017-2028)
    Figure 28. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size Share by Country (2017-2028)
    Figure 29. Germany Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 30. France Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. U.K. Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. Italy Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 33. Russia Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 34. Nordic Countries Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 35. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY (2017-2028) & (US$ Million)
    Figure 36. Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size Market Share by Indication (2017-2028)
    Figure 37. Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size Market Share by End Users (2017-2028)
    Figure 38. Asia Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size Share by Region (2017-2028)
    Figure 39. China Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 40. Japan Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 41. South Korea Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 42. Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 43. India Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 44. Australia Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 45. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY (2017-2028) & (US$ Million)
    Figure 46. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size Market Share by Indication (2017-2028)
    Figure 47. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size Market Share by End Users (2017-2028)
    Figure 48. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size Share by Country (2017-2028)
    Figure 49. Mexico Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 50. Brazil Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 51. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY (2017-2028) & (US$ Million)
    Figure 52. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size Market Share by Indication (2017-2028)
    Figure 53. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size Market Share by End Users (2017-2028)
    Figure 54. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size Share by Country (2017-2028)
    Figure 55. Turkey Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 56. Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 57. UAE Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 58. Pfizer Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
    Figure 59. GlaxoSmithKline Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
    Figure 60. AstraZeneca Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
    Figure 61. Boehringer Ingelheim Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
    Figure 62. Teva Pharmaceutical Industries Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
    Figure 63. Takeda Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
    Figure 64. Baxter Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
    Figure 65. Grifols Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
    Figure 66. CSL Behring Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
    Figure 67. Kamada Ltd Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
    Figure 68. Chiesi Pharmaceuticals Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
    Figure 69. Kedrion Group Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
    Figure 70. Vertex Pharmaceuticals Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
    Figure 71. ProMetic Life Sciences Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
    Figure 72. Bottom-up and Top-down Approaches for This Report
    Figure 73. Data Triangulation
    Figure 74. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Pfizer
GlaxoSmithKline
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceutical Industries
Takeda
Baxter
Grifols
CSL Behring
Kamada Ltd
Chiesi Pharmaceuticals
Kedrion Group
Vertex Pharmaceuticals
ProMetic Life Sciences
Frequently Asked Questions
Alpha 1 Antitrypsin Deficiency Treatment report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Alpha 1 Antitrypsin Deficiency Treatment report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Alpha 1 Antitrypsin Deficiency Treatment report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Chrome Plated Bar

Chrome Plated Bar market is segmented by Type and by Application. Players, stakeholders, and othe ... Read More